CL2012001030A1 - Polipeptido inmunomodulador derivado de la il-2 que comprende varias mutaciones respecto a la secuencia de il-2 nativa que inhibe preferencialmente la actividad de il- 2 sobre celulas t reguladoras in vitro; proteína de fusión que lo comprende; y su uso para tratar cancer. - Google Patents

Polipeptido inmunomodulador derivado de la il-2 que comprende varias mutaciones respecto a la secuencia de il-2 nativa que inhibe preferencialmente la actividad de il- 2 sobre celulas t reguladoras in vitro; proteína de fusión que lo comprende; y su uso para tratar cancer.

Info

Publication number
CL2012001030A1
CL2012001030A1 CL2012001030A CL2012001030A CL2012001030A1 CL 2012001030 A1 CL2012001030 A1 CL 2012001030A1 CL 2012001030 A CL2012001030 A CL 2012001030A CL 2012001030 A CL2012001030 A CL 2012001030A CL 2012001030 A1 CL2012001030 A1 CL 2012001030A1
Authority
CL
Chile
Prior art keywords
regulatory
native
vitro
cells
activity
Prior art date
Application number
CL2012001030A
Other languages
English (en)
Inventor
Monzon Kalet Leon
Portilla Tania Carmenate
Matinez Karina Garcia
Davila Agustin Bienvenido Lage
Rodriguez Perez
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43646474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001030(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Publication of CL2012001030A1 publication Critical patent/CL2012001030A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2012001030A 2009-11-27 2012-04-23 Polipeptido inmunomodulador derivado de la il-2 que comprende varias mutaciones respecto a la secuencia de il-2 nativa que inhibe preferencialmente la actividad de il- 2 sobre celulas t reguladoras in vitro; proteína de fusión que lo comprende; y su uso para tratar cancer. CL2012001030A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20090203A CU23734A1 (es) 2009-11-27 2009-11-27 Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas

Publications (1)

Publication Number Publication Date
CL2012001030A1 true CL2012001030A1 (es) 2012-07-20

Family

ID=43646474

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001030A CL2012001030A1 (es) 2009-11-27 2012-04-23 Polipeptido inmunomodulador derivado de la il-2 que comprende varias mutaciones respecto a la secuencia de il-2 nativa que inhibe preferencialmente la actividad de il- 2 sobre celulas t reguladoras in vitro; proteína de fusión que lo comprende; y su uso para tratar cancer.

Country Status (24)

Country Link
US (1) US8759486B2 (es)
EP (1) EP2505206B1 (es)
JP (1) JP5680661B2 (es)
KR (1) KR101484590B1 (es)
CN (1) CN102665754B (es)
AR (1) AR079197A1 (es)
AU (1) AU2010324254B2 (es)
BR (1) BR112012012025B8 (es)
CA (1) CA2781173C (es)
CL (1) CL2012001030A1 (es)
CO (1) CO6501124A2 (es)
CU (1) CU23734A1 (es)
EA (1) EA021867B1 (es)
EC (1) ECSP12011803A (es)
ES (1) ES2643465T3 (es)
HK (1) HK1169961A1 (es)
MX (1) MX2012006077A (es)
MY (1) MY162324A (es)
NZ (1) NZ599792A (es)
PE (1) PE20121636A1 (es)
SG (1) SG181089A1 (es)
TN (1) TN2012000182A1 (es)
WO (1) WO2011063770A2 (es)
ZA (1) ZA201203762B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
CA2925421C (en) 2013-09-24 2023-08-29 Medicenna Therapeutics, Inc. Interleukin-2 fusion proteins and uses thereof
CN106456730A (zh) 2014-03-17 2017-02-22 德意志联邦共和国代表主席罗伯特·科赫研究所 用于诱导或延长细胞之细胞毒性免疫应答的方法的药物
JP6592505B2 (ja) * 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
BR112019005944A2 (pt) 2016-09-28 2019-06-11 Musc Foudation For Res Development anticorpos que se ligam à interleucina 2 e usos dos mesmos
CU24483B1 (es) 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
JP7433051B2 (ja) 2017-06-19 2024-02-19 メディシナ セラピューティクス インコーポレイテッド Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
BR112020019639A2 (pt) * 2018-03-28 2021-01-05 Ascendis Pharma Oncology Division A/S Conjugados de il-2
TW202003551A (zh) 2018-03-28 2020-01-16 美商必治妥美雅史谷比公司 介白素-2/介白素-2受體阿法融合蛋白及其使用方法
EP3802587A4 (en) * 2018-06-07 2022-03-23 Prottech Inc. PHARMACEUTICAL COMPOSITION COMPRISING A FUSION PROTEIN AND USE THEREOF
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations Inc TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
MX2023002648A (es) * 2020-09-04 2023-04-05 Shandong Simcere Biopharmaceutical Co Ltd Mutante de il-2 y aplicacion de este.
EP4232071A1 (en) 2020-10-23 2023-08-30 Asher Biotherapeutics, Inc. Fusions with cd8 antigen binding molecules for modulating immune cell function
CA3195260A1 (en) 2020-10-29 2022-05-05 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
KR20240026905A (ko) 2021-04-30 2024-02-29 티젠 파마 에스에이 림프구의 단일 용기 확장
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2024097864A1 (en) 2022-11-02 2024-05-10 Tigen Pharma Sa Expansion of lymphocytes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
JP3024311B2 (ja) 1991-10-03 2000-03-21 味の素株式会社 Ｉｌ−２受容体重鎖に結合するポリペプチド
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
JP2002528389A (ja) 1998-08-21 2002-09-03 イエダ リサーチ アンド デベロップメント カンパニー リミテッド Ｉｌ−２及びその類似体から誘導される抗炎症性ペプチド
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
WO2008003473A2 (en) * 2006-07-06 2008-01-10 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
US8906356B2 (en) * 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen

Also Published As

Publication number Publication date
CO6501124A2 (es) 2012-08-15
EP2505206B1 (en) 2017-09-27
KR20120106728A (ko) 2012-09-26
EA021867B1 (ru) 2015-09-30
US20120315245A1 (en) 2012-12-13
JP2013512200A (ja) 2013-04-11
ES2643465T3 (es) 2017-11-23
ZA201203762B (en) 2013-01-30
MX2012006077A (es) 2012-09-07
WO2011063770A2 (es) 2011-06-03
CN102665754A (zh) 2012-09-12
PE20121636A1 (es) 2012-12-03
CU23734A1 (es) 2011-11-15
SG181089A1 (en) 2012-07-30
EP2505206A2 (en) 2012-10-03
ECSP12011803A (es) 2012-07-31
BR112012012025B8 (pt) 2021-05-25
EA201290395A1 (ru) 2012-10-30
BR112012012025B1 (pt) 2021-05-11
WO2011063770A3 (es) 2011-09-09
KR101484590B1 (ko) 2015-01-22
JP5680661B2 (ja) 2015-03-04
NZ599792A (en) 2014-01-31
HK1169961A1 (en) 2013-02-15
MY162324A (en) 2017-05-31
CN102665754B (zh) 2014-03-12
AU2010324254A1 (en) 2012-05-31
CA2781173A1 (en) 2011-06-03
CA2781173C (en) 2015-10-13
AR079197A1 (es) 2012-01-04
AU2010324254B2 (en) 2014-01-09
TN2012000182A1 (en) 2013-12-12
BR112012012025A2 (pt) 2016-05-17
US8759486B2 (en) 2014-06-24

Similar Documents

Publication Publication Date Title
CL2012001030A1 (es) Polipeptido inmunomodulador derivado de la il-2 que comprende varias mutaciones respecto a la secuencia de il-2 nativa que inhibe preferencialmente la actividad de il- 2 sobre celulas t reguladoras in vitro; proteína de fusión que lo comprende; y su uso para tratar cancer.
CL2013001107A1 (es) Polipeptido derivado de la il-2 con actividad agonista; proteina de fusion que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar cancer y enfermedades infecciosas cronicas.
HRP20181989T1 (hr) Sredstva za i postupci određivanja biološke aktivnosti neurotoksičnih polipeptida u stanicama
IL261151A (en) Water-soluble membrane proteins, methods for their preparation and use
BRPI1008740A2 (pt) Proteínas pesticidas e métodos para seu uso.
CL2015000606A1 (es) Polipeptidos que contienen fc con glicosilacion alterada y función efectora reducida.
BRPI1008061A2 (pt) polipetídeos recombinantes estendidos e composições compreendendo os mesmos
CR20110640A (es) Derivados de amiloide p sérico/de suero y su preparación y uso
BR112013010834A2 (pt) polipeptídeos fator ix modificados e usos dos mesmos
BR112012013148A2 (pt) formulação farmacêutica e uso
BRPI1009413A2 (pt) emulsões e adesivos contendo proteína e produção e uso dos mesmos
DK3572091T3 (da) Modificerede relaxinpolypeptider og anvendelser deraf
CL2013002361A1 (es) Metodo para medir actividad de células natural killer (nk); kit para medir dicha actividad; proteína de fusión; composicion para activar células nk; polipéptido, oligonucleótido, vector y célula hospedera que comprenden la proteína;
BR112012004731A2 (pt) peptídeos derivados de wnt10 e uso dos mesmos
CL2012000238A1 (es) Polipéptido del factor ix; secuencia de adn que lo codifica; célula huésped eucariota; procedimiento de producción; conjugado; composición que lo comprende; y su uso para el tratamiento de la hemofilia b.
BR112013001423A2 (pt) método, método in vitro, uso e kit útil para realizar o método
BR112012011464A2 (pt) proteínas encapsuladas de óleo modificadas e seu uso
BRPI1008887A2 (pt) peptídeos de foxm1 e vacinas contendo os mesmo
EP3604546A4 (en) SYSTEM OF PROTEIN EXPRESSION IN A PLANT CELL AND ASSOCIATED USE
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
CL2013001128A1 (es) Composicion que comprende penflufeno y oxido de cobre y/o tiabendazol; y su uso para proteger la madera frente a basidiomicetos.
EA201290541A1 (ru) Модифицированные бычьи соматотропиновые полипептиды и их применение
BR112013011152A2 (pt) proteína beta-glucocerebrosidase recombinante variante, composição e uso da proteína betaglucocerebrosidase recombinante variante
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
CA142107S (en) Log splitting wedge